Molbio Diagnostics’ initial public offering, valued at roughly Rs 940 crore, entered its final subscription day on Monday with a grey‑market premium (GMP) of Rs 152, suggesting a potential listing gain of about 19 percent over the top of its price band.
Subscription figures and pricing range
The IPO opened on Aug. 10 with a price band set between Rs 768 and Rs 807 per share. By 1:10 p.m. on Aug. 12, the issue was subscribed 15.12 times overall. Institutional investors showed strong interest: qualified institutional buyers (QIBs) subscribed 19.17 times, non‑institutional investors (NIIs) 26.94 times, while retail individual investors (RIIs) subscribed 7.77 times.
The lot size is 18 shares, making the minimum retail investment Rs 14,526 based on the upper price band.
Grey‑market premium and possible listing price
Current grey‑market data shows a premium of Rs 152, which would place the likely listing price near Rs 959. That figure represents an 18.84 percent premium over the upper limit of the IPO band. Grey‑market prices are unofficial and can shift before the official debut, so the premium does not guarantee the eventual trade price.
Related: Akums CDSL Ceigall Power Mech in focus
The GMP figure is often watched as a barometer of market sentiment, but it remains a speculative metric. Traders who buy in the grey market are essentially betting that demand will push the share price above the issue price, while others may view the premium as an over‑optimistic signal.
Proceeds are earmarked primarily for research and development, including the establishment of a Center of Excellence and associated office space. Some funds will also be allocated to acquiring plant, machinery, and equipment for facilities in Goa and Visakhapatnam, with the remainder supporting general corporate purposes.
Financially, the company reported total income of Rs 1,455.17 crore for FY 26, up 41.4 percent from the prior year. Profit after tax grew 18.4 percent to Rs 164.14 crore, and EBITDA increased 27.9 percent to Rs 328.24 crore. These figures reflect a steady expansion in both revenue and profitability.
The IPO’s lead manager is Kotak Mahindra Capital Co. Ltd., with Kfin Technologies Ltd. serving as the registrar. The allotment is slated for Aug. 13, with refunds beginning Aug. 14 and shares credited on Aug. 14. Trading is expected to start on Aug. 17.
Related: Hero MotoCorp shares rise 3% after strong Q1
Founded in October 2000, the firm operates globally in the point‑of‑care molecular diagnostics space, developing rapid tests for infectious and non‑communicable diseases. Its focus on quick, accurate diagnostics aligns with growing demand for decentralized testing solutions.
From a broader perspective, the IPO’s size and the observed GMP highlight a continued appetite among investors for health‑tech listings. While the premium suggests optimism, the ultimate performance will depend on how the company leverages its capital to sustain growth and meet market expectations.
Investors are reminded that IPO investments carry market risk. Review the prospectus thoroughly and consider advice from financial advisers before committing funds.
